ReviewACS pharmacology & translational science2026
Emerging Role of Ferroptosis in Chemotherapy-Associated Hepatorenal Toxicity: Mechanistic Insights and Toxicological Perspectives.
Review in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy-induced hepatorenal toxicity is one of the most predominant dose-limiting obstacles in oncological pharmacotherapy, and the molecular mechanisms surrounding its pathogenesis are still poorly defined. Lipid peroxide toxicity-induced, iron-dependent, nonapoptotic types of regulated cell death called ferroptosis have emerged as a mechanically important process in the organ injury caused by chemotherapy. In this Keynote Review, we will summarize recent evidence showing the implication of ferroptosis in liver and kidney toxicity of platinum-based drugs, anthracycline drugs, tyrosine kinase inhibitors, and some targeted drugs. We identify key mechanisms underlying ferroptosis, including abnormalities of the axis of system Xc
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.